Is Now An Opportune Moment To Examine Insulet Corporation (NASDAQ:PODD)?
If You Invested $100 In This Stock 10 Years Ago, You Would Have $600 Today
Insulet Is Maintained at Buy by BTIG
Raymond James Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $260
BTIG Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $260
Express News | Insulet Corp : Btig Raises Target Price to $260 From $250
Is Insulet Corporation (NASDAQ:PODD) The Top Stock With Improving Technical Ratings According To Piper Sandler?
We Like These Underlying Return On Capital Trends At Insulet (NASDAQ:PODD)
National Campaign Launches to Combat Diabetes Stigma Using Comedy
Insulet Corp (PODD) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Raised Guidance
Baird Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $280
Here's Why ClearBridge Growth Strategy Increased Its Position in Insulet Corporation (PODD)
Infusion Pumps and Devices Technologies and Global Market Report 2024: Company Profiles of Market Leaders, Including Baxter, BD, Insulet Corp., Medtronic and B. Braun - ResearchAndMarkets.com
Medtronic Issues Recall for MiniMed Insulin Pumps Over Battery Issues
BDX Upped to Buy by Citi, TNDM Put on Negative Catalyst Watch
Fidelity Growth Strategies Fund Trimmed Insulet Corporation (PODD) to Manage the Position Size
Citi Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $275
Express News | Insulet Corp : Citigroup Raises Target Price to $275 From $250
Insulet to Announce Third Quarter 2024 Financial Results on November 7, 2024
Insulet's (NASDAQ:PODD) Investors Will Be Pleased With Their Respectable 48% Return Over the Last Five Years